906565-52-4

Basic information

• Product Name: tert-butyl 4-((4-(Methoxycarbonyl)-2-Methoxyphenoxy)Methyl)piperidine-1-carboxylate
• Synonyms: tert-butyl 4-((4-(Methoxycarbonyl)-2-Methoxyphenoxy)Methyl)piperidine-1-carboxylate
• CAS NO: 906565-52-4
• Molecular Weight: 379.453
• Mol File: 906565-52-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-((4-(Methoxycarbonyl)-2-Methoxyphenoxy)Methyl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-((4-(Methoxycarbonyl)-2-Methoxyphenoxy)Methyl)piperidine-1-carboxylate(906565-52-4)
• EPA Substance Registry System: tert-butyl 4-((4-(Methoxycarbonyl)-2-Methoxyphenoxy)Methyl)piperidine-1-carboxylate(906565-52-4)

Safety Data

• Hazardous Substances Data: 906565-52-4(Hazardous Substances Data)

Upstream product

• 3943-74-6 4-hydroxy-3-methoxybenzoic acid methyl ester 
• 166815-96-9 N-tert-butoxycarbonyl-4-(4-toluenesulphonyloxymethyl)piperidine 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 

Downstream Products

• 906565-53-5 methyl 5-methoxy-4-(1-methylpiperidin-4-ylmethoxy)-2-nitrobenzoate 
• 635678-10-3 methyl 2-amino-5-methoxy-4-(1-methylpiperidin-4-ylmethoxy)benzoate 
• 635678-09-0 methyl 3-methoxy-4-(1-methylpiperidin-4-ylmethoxy)benzoate 
• 264208-69-7 6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-3,4-dihydroxyquinazolin-4-one 

Relevant articles and documents

QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF

Related to a quinazoline compound serving as an EFGR triple mutation inhibitor and applications thereof. Specifically, disclosed are a compound as represented by the following formula (I), a pharmaceutical composition comprising the compound of formula (I

Fluorine-18 labeling of 6,7-disubstituted anilinoquinazoline derivatives for positron emission tomography (PET) imaging of tyrosine kinase receptors: Synthesis of18F-Iressa and related molecular probes

Inhibitors of tyrosine kinase enzymatic activity represent a promising new class of antineoplastic agents. Although clinical studies performed over the last decade give more insight on the potential therapeutic applications of such drugs, identification of the individual patients who might benefit from them remains a major challenge. We have developed a synthetic strategy for the production of a wide variety of radiolabeled 6,7-disubstituted 4-anilinoquinazolines suitable for noninvasive imaging of tyrosine kinase receptors to predict therapy effectiveness. Three new F-18 labeled radiopharmaceuticals based on the therapeutic agents Tarceva, Iressa, and ZD6474 were synthesized. Decay-corrected yields varied between 25 and 40% for a total synthesis time of 120 min, thus providing F-18 labeled tyrosine kinase inhibitors in quantities and times practical for use as PET radiopharmaceuticals. Copyright